Dasatinib and quercetin (D+Q) have shown senolytic activity in peripheral tissues and rodent brains. The critical question for Alzheimer's disease is whether D+Q specifically clears p16Ink4a-high senescent neurons that accumulate near plaques, without eliminating adjacent neurons that may lack clean senescence biomarkers. Safety concern: BCL2/BCL-xL inhibition may be toxic to non-senescent neurons. Falsifiable prediction: D+Q treatment (5 cycles, 2 days on/5 days off) in 5xFAD mice should reduce p16Ink4a+ cells by ≥50% with <5% off-target neuronal loss by NeuN counts.